Transcatheter Tricuspid Valve Replacement After Failed Transcatheter Annuloplasty and Edge-to-Edge Repair
Key result
EVOQUE TTVR resolves severe TR after failed prior interventions in a case report.
- n=1
Why the study?
The feasibility of EVOQUE transcatheter tricuspid valve replacement after failed percutaneous tricuspid annuloplasty and edge-to-edge repair had not been reported.
Does transcatheter tricuspid valve replacement improve outcomes in a patient with severe tricuspid regurgitation after failed annuloplasty and edge-to-edge repair?
Population
An 80-year-old man with severe TR after failed annuloplasty and edge-to-edge repair
Comparison
TTVR with a 48-mm EVOQUE valve
Design
Case report
Follow-up
1 month
Authors
Discussion
Loading...
Member takes
Implication
May support use after failed tricuspid interventions in select cases; hypothesis-generating for durability and outcomes in prospective studies.
Study Design
Type
Case Report (n=1)
Structured PICO
Does transcatheter tricuspid valve replacement improve outcomes in a patient with severe tricuspid regurgitation after failed annuloplasty and edge-to-edge repair?
P
Population
An 80-year-old man with atrial fibrillation and severe tricuspid regurgitation after failed percutaneous annuloplasty and edge-to-edge repair (n=1).
I
Intervention
Transcatheter tricuspid valve replacement (TTVR) with a 48-mm EVOQUE valve.
O
Outcome
Clinical and echocardiographic outcomes (residual TR, paravalvular leak, NYHA functional class) at 1 month.surrogate
Transcatheter tricuspid valve replacement is a feasible and effective treatment option for severe tricuspid regurgitation even in complex cases with prior failed transcatheter annuloplasty and edge-to-edge repair.
Cite This Study
Toggweiler et al. (2025) conducted a case report in Severe tricuspid regurgitation (n=1). Transcatheter tricuspid valve replacement (TTVR) with EVOQUE valve was evaluated on Residual TR, paravalvular leak, and NYHA functional class. Transcatheter tricuspid valve replacement with the EVOQUE valve successfully treated severe tricuspid regurgitation after failed prior interventions, resulting in no residual TR at 1 month.